SightfileU.S. market data from official filings

Companies › LYRA

LYRA THERAPEUTICS INC (LYRA)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001327273 · EDGAR filings · Updated 2026-05-15

LYRA THERAPEUTICS INC (LYRA) has reported institutional ownership of 5.9%, with 1 institutional managers holding positions valued at $51.1K per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings, triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).

Institutional ownership
5.9%
Institutional managers
1
Reported 13F value
$51.1K
Insider activity
16 trans.
−$555.1K net selling
Data flags
4 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, LYRA THERAPEUTICS INC has 1 institutional holders and institutional ownership of 5.9%.

Insider activity

Insiders reported 16 transactions (0 buys, 16 sells) across 4 reporting insiders, with a net reported value of −$555.1K.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-03-31 (recurring since 2022-03-09) — source filing. The authoritative details are those stated in the filing itself.
Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2026-03-16 (recurring since 2024-07-23) — source filing. The authoritative details are those stated in the filing itself.
Active triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04), most recently filed 2026-02-27 (recurring since 2026-02-27) — source filing. The authoritative details are those stated in the filing itself.
Active non-reliance notice on previously issued financial statements (8-K Item 4.02), most recently filed 2022-10-26 (recurring since 2022-10-26) — source filing. The authoritative details are those stated in the filing itself.

Related companies

Adial Pharmaceuticals Inc (ADIL) · BGM Group Ltd (BGM) · SILEXION THERAPEUTICS CORP (SLXN) · PROPANC BIOPHARMA INC (PPCB) · Check Cap Ltd (MBAI) · CLEARMIND MEDICINE INC (CMND)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-05-15.